Unlock the potential of antisense technology. Discover how RNA therapeutics can target previously ‘undruggable’ molecules for effective manipulation.
(3 min read)
RNA Therapeutics: A Focus on Antisense
read more
Stay Updated! Subscribe to The Primer
Share
Epigenetics: Rewriting the Future of Aging
The field of epigenetics is progressing quickly, presenting a novel and exciting approach for precision medicine by altering gene expression with high precision and reversibility without changing the underlying DNA sequence.
(3 min read)
The Immune System: Friend & Sometimes Foe
The immune system is a complicated network of organs, cells, and signaling molecules. Without it, we fall prey to dangerous pathogens in the environment.
(3 min read)
Breaking Barriers with CRISPR’s Regulatory Approval
CRISPR is a revolutionary gene-editing tool that catalyzes a new era in precision medicine and drives a fierce ethical debate.
(3 min read)
Unlock the Language of Cells with Cell Signaling
Understand cell communication and how different hormones, receptors, and ligands impact the messages sent to cells.
(3 min read)
Antisense, RNAi and micro-RNA Explained
RNA-based drug therapy has taken the biotech world by storm, reshaping treatment landscapes with its ability to target “undruggable” areas and provide personalized patient solutions.
(3 min read)
Beyond GLP-1: Biotech Hacks For Obesity
Obesity is far more complex than the chronic consumption of too many calories. Unraveling obesity’s origins and finding effective therapies requires navigating a…
(3 min read)
Unlocking the Potential of CRISPR
Uncover the power of CRISPR as a game-changing tool for genome editing. Learn how scientists are harnessing CRISPR to make unprecedented advancements in genetic engineering.
(3 min read)
The Power of mRNA: Vaccines, Treatments, and the Road Ahead
The COVID-19 vaccine provided more than a defense against a deadly virus; it introduced mRNA’s transformative journey in modern healthcare.
(3 min read)
New Gene Therapy Drug Explained
In March 2023, Novartis’ (Basel, Switzerland), shared its latest data concerning Zolgensma. The findings reveal sustained durability up to 7.5 years post-dosing, with a 100% achievement of all assessed milestones in children treated before the onset of spinal muscular...
Biotech Primer is your go-to source for interactive training across the biotechnology, pharmaceutical, molecular diagnostics, and medical device sectors. Explore a range of in-depth biotech courses designed to deepen your understanding of key principles and applications in the field.